A Phase I, Randomised, Single-blind Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567 in Healthy Volunteers Using Prednisolone as Positive Control

Trial Profile

A Phase I, Randomised, Single-blind Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567 in Healthy Volunteers Using Prednisolone as Positive Control

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs AZD 9567 (Primary) ; Prednisolone
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 May 2017 Treatment arms has been increases from 5 to 9 (three doses of prednisolone was tested, 5 mg, 20 mg and 40 mg) and patients number also increases.
    • 29 May 2017 Planned number of patients changed from 64 to 95, as per detailed description of ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top